Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 168 current clinical trials in our China register. 108 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Cadonilimab, Cyclophosphamide and Nab-paclitaxel. The most-studied condition is Gastric Cancer.

ClinicalTrials.gov trials by status

Recruiting10864%
Not yet open4627%
Active, closed64%
By invitation85%

Trials by phase

Observational4426%
Not applicable3621%
Phase EARLY_PHASE12615%
Phase 22615%
Phase 1159%
Phase 1/285%
Phase 374%
Phase 453%
Phase 2/311%

Clinical trials sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

168 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC NCT07474103 · Rectal Cancer, Adenocarcinoma Drugs: Capecitabine, Liposomal Irinotecan, Oxaliplatin	Not applicable	Recruiting	2025-11	China
Using Artificial Intelligence to Improve Radiologists' Performance in Radiology Report Writing: a Randomised Controlled Trial NCT06907927 · Healthy	Not applicable	Recruiting	2025-04	China
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung) NCT07059923 · Lung Cancer (Diagnosis)	Observational	Recruiting	2025-07	China
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors NCT07301814 · ClinicalTrials.gov ↗ · Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma Cancer	Observational	Recruiting	2025-09	China
Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver） NCT06536998 · ClinicalTrials.gov ↗ · Liver Cancer	Observational	Recruiting	2024-08	China
Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases NCT07090200 · ClinicalTrials.gov ↗ · Respiratory Diseases, Cardiovascular Diseases, Cerebrovascular Diseases	Not applicable	Recruiting	2025-09	China
Research on the Mechanism Affecting Progression of Bronchiectasis NCT05731427 · ClinicalTrials.gov ↗ · Bronchiectasis	Observational	Recruiting	2021-02	China
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer NCT06826079 · ClinicalTrials.gov ↗ · Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy	Phase 2	Recruiting	2024-11	China
Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment NCT06653478 · ClinicalTrials.gov ↗ · Artificial Intelligence, Deep Learning, Lung Cancer	Observational	Recruiting	2022-06	China
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma NCT07177443 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma Drugs: Cisplatin, Serplulimab	Phase 3	Recruiting	2025-09	China
Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment NCT05426135 · ClinicalTrials.gov ↗ · Artificial Intelligence, Deep Learning, Lung Cancer	Observational	Recruiting	2022-06	China
Immunoinflammatory Regulation of Esketamine in Septic Patients NCT04843982 · ClinicalTrials.gov ↗ · Esketamine, Sepsis, Inflammatory Response Drug: Esketamine hydrochloride	Phase 4	Recruiting	2021-07	China
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors NCT06720324 · ClinicalTrials.gov ↗ · Hematologic Malignancy Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2024-12	China
Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary） NCT06537037 · ClinicalTrials.gov ↗ · Urologic Cancer	Observational	Recruiting	2024-08	China
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma NCT07301827 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Not applicable	Recruiting	2025-06	China
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer NCT06491472 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: Gemcitabine, Ivonescimab, Nab-paclitaxel	Phase 2	Recruiting	2024-07	China
The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis NCT06346938 · ClinicalTrials.gov ↗ · Bronchiectasis	Observational	Recruiting	2024-03	China
Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma NCT06383520 · ClinicalTrials.gov ↗ · Malignant Neoplasm of Liver	Phase EARLY_PHASE1	Recruiting	2023-09	China
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver) NCT07059936 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2025-07	China
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients NCT05994274 · ClinicalTrials.gov ↗ · Heart Transplant Failure and Rejection	Observational	Recruiting	2023-12	China
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis NCT06685887 · ClinicalTrials.gov ↗ · Gastric Cancer Drug: Hipec	Phase 2	Recruiting	2025-02	China
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer NCT06802666 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy Drugs: Capecitabine, Ivonescimab, Oxaliplatin	Phase 2	Recruiting	2024-10	China
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia NCT05445011 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Cyclophosphamide, Fludarabine	Phase 1	Recruiting	2022-06	China
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC NCT06542588 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	2024-07	China
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors NCT06843629 · ClinicalTrials.gov ↗ · Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer	Observational	Recruiting	2024-10	China
The Prognosis of Patients After PCI：a Multi-center Study in China NCT05614050 · ClinicalTrials.gov ↗ · Inflammation	Observational	Recruiting	2022-11	China
RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI NCT05131750 · ClinicalTrials.gov ↗ · hsCRP	Observational	Recruiting	2021-05	China
Assessment of the Predictive Value of Anti-beta1AR and Anti-L-CaC Antibodies in the Evolution to Dilated Cardiomyopathy in Patients With Acute Viral Myocarditis NCT06742008 · ClinicalTrials.gov ↗ · Viral Myocarditis	Observational	Recruiting	2024-12	China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Drugs: Bortezomib, Carfilzomib, Cisplatin	Phase 2	Recruiting	2023-10	China
Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy NCT06741995 · ClinicalTrials.gov ↗ · Dilated Cardiomyopathy (DCM)	Observational	Recruiting	2024-12	China
Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis NCT06436534 · ClinicalTrials.gov ↗ · Rhinitis, Allergic	Not applicable	Recruiting	2024-05	China
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer NCT06717880 · ClinicalTrials.gov ↗ · Advanced Malignancies Drugs: Bevacizumab, IBI363	Phase 1	Recruiting	2023-07	China
Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis NCT07347860 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)	Phase EARLY_PHASE1	Recruiting	2026-01	China
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer NCT03573791 · ClinicalTrials.gov ↗ · Rectal Cancer, Cancer of Rectum, Cancer of the Rectum	Observational	Recruiting	2018-05	China
Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） NCT07699029 · ClinicalTrials.gov ↗ · Posterior Circulation Ischemic Stroke	Not applicable	Recruiting	2026-07	China
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma NCT06484153 · ClinicalTrials.gov ↗ · To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer	Phase 2	Recruiting	2024-07	China
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus NCT07776080 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma Drugs: Iparomlimab and Tuvonralimab, Lenvatinib	Phase 2	Recruiting	2026-10	China
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer NCT07810088 · ClinicalTrials.gov ↗ · HR+ / HER2- Advanced Breast Cancer	Phase 2	Recruiting	2025-06	China
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma NCT06693973 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma (B-NHL) Drug: AcNK-Sup003 cell	Phase EARLY_PHASE1	Recruiting	2023-12	China
Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia. NCT07233889 · ClinicalTrials.gov ↗ · Hypophosphatemia	Not applicable	Recruiting	2025-11	China
The Clinical Study on the Treatment of SSc With UTAA91 Injection. NCT07000682 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc) Drug: UTAA91	Phase EARLY_PHASE1	Recruiting	2025-05	China
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer NCT06487429 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	2024-05	China
A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT NCT07400536 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma	Phase 3	Recruiting	2026-04	China
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma NCT06244225 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	2024-01	China
Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study NCT05875740 · ClinicalTrials.gov ↗ · Sepsis, Inflammatory Response	Observational	Recruiting	2023-09	China
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer NCT07689643 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase EARLY_PHASE1	Recruiting	2026-04	China
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors NCT07301801 · ClinicalTrials.gov ↗ · Malignant Tumors, SSTR2, PET Drug: 18F-FDG	Phase EARLY_PHASE1	Recruiting	2025-06	China
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma NCT07548697 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)	Phase EARLY_PHASE1	Recruiting	2026-04	China
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis NCT07547735 · ClinicalTrials.gov ↗ · Knee Osteoarthritis Drug: UC-MSCs	Phase 2	Recruiting	2025-03	China
A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer NCT06000917 · ClinicalTrials.gov ↗ · Breast Cancer, Neoadjuvant	Phase 2	Recruiting	2023-05	China
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer NCT07689656 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1/2	Recruiting	2026-06	China
Fecal Microbiota Transplantation for the Treatment of ICU Delirium NCT07348471 · ClinicalTrials.gov ↗ · Delirium	Not applicable	Recruiting	2026-03	China
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma NCT06367075 · ClinicalTrials.gov ↗ · Advanced Soft-tissue Sarcoma Drugs: Adriamycin, Cadonilimab	Phase 2	Recruiting	2024-10	China
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492 · ClinicalTrials.gov ↗ · NK T-Cell Lymphoma, CART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies	Phase 1	Recruiting	2024-10	China
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. NCT07429721 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase EARLY_PHASE1	Recruiting	2026-03	China
Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma NCT05830812 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Stage I	Observational	Recruiting	2023-01	China
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study NCT06234007 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	2023-12	China
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients NCT07680816 · ClinicalTrials.gov ↗ · Sepsis, Critical Illness, Immunosuppression	Observational	Recruiting	2026-06	China
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus NCT07339332 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Phase EARLY_PHASE1	Recruiting	2026-01	China
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study NCT06791889 · ClinicalTrials.gov ↗ · Sepsis, Bloodstream Infections, Critically Ill Intensive Care Unit Patients	Observational	Recruiting	2024-09	China
CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus NCT06349343 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1	Recruiting	2025-02	China
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors NCT06490211 · ClinicalTrials.gov ↗ · Urinary System Carcinoma	Observational	Recruiting	2023-11	China
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors NCT06735495 · ClinicalTrials.gov ↗ · B-Cell Lymphoblastic Leukemia/Lymphoma	Phase 1/2	Recruiting	2024-11	China
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial NCT06228794 · ClinicalTrials.gov ↗ · Multiple Myeloma	Observational	Recruiting	2024-04	China
Phase I Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis NCT06463847 · ClinicalTrials.gov ↗ · Knee Osteoarthritis Drug: UC-MSCs	Phase 1	Recruiting	2024-06	China
Study on Disease Progression and Nutritional Status in Bronchiectasis NCT06344000 · ClinicalTrials.gov ↗ · Bronchiectasis	Observational	Recruiting	2024-04	China
CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer NCT07776067 · ClinicalTrials.gov ↗ · Gastric Cancer	Observational	Recruiting	2026-04	China
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis NCT06357741 · ClinicalTrials.gov ↗ · Knee Osteoarthritis Drug: Denosumab	Observational	Recruiting	2021-08	China
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus NCT06400537 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1	Recruiting	2024-07	China
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection NCT07001956 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA) Drug: UTAA91	Phase EARLY_PHASE1	Recruiting	2025-05	China
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer NCT06367088 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer, Cadonilimab Drug: Cadonilimab	Phase 2	Recruiting	2024-05	China
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases NCT07441525 · ClinicalTrials.gov ↗ · Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura, Evans Syndrome Drug: CART	Phase EARLY_PHASE1	Recruiting	2026-02	China
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial NCT06654011 · ClinicalTrials.gov ↗ · Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma Drugs: Cadonilimab, IN10018, Nab-paclitaxel	Phase 2	Recruiting	2025-02	China
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases NCT07092202 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy Drugs: Furmonertinib, Pemetrexed	Phase 4	Recruiting	2025-04	China
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis NCT07172035 · ClinicalTrials.gov ↗ · Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS)	Observational	Recruiting	2025-08	China
Clinical Application of FL-091 Radionuclide Imaging in Diagnosis and Staging of Malignant Tumors NCT06977945 · ClinicalTrials.gov ↗ · Malignant Tumors With Positive NTSR1 Expression	Observational	Recruiting	2024-10	China
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC NCT07355972 · ClinicalTrials.gov ↗ · SSc-Systemic Sclerosis	Phase EARLY_PHASE1	Recruiting	2026-01	China
FL-261 Imaging for Cancer Diagnosis and Staging NCT07510321 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Head & Neck Cancer	Observational	Recruiting	2025-11	China
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM NCT06503107 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	2024-04	China
TIPS With or Without BCAA NCT07281846 · ClinicalTrials.gov ↗ · BCAA, Cirrhosis, Portal Hypertension Related to Cirrhosis	Not applicable	Recruiting	2025-11	China
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus NCT06106893 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1/2	Recruiting	2024-01	China
A Study of YKST02 in Participants With Primary IgA Nephropathy NCT07498673 · ClinicalTrials.gov ↗ · Primary IgA Nephropathy Drug: YKST02	Phase EARLY_PHASE1	Recruiting	2026-05	China
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults NCT07470073 · ClinicalTrials.gov ↗ · ALL (Acute B-Lymphoblastic Leukemia)	Phase EARLY_PHASE1	Recruiting	2026-04	China
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies NCT07240974 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Malignancies	Phase EARLY_PHASE1	Recruiting	2025-10	China
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) NCT06519565 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia	Phase EARLY_PHASE1	Recruiting	2024-08	China
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. NCT05747729 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma	Phase 1/2	Recruiting	2023-06	China
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors NCT07552467 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Breast Cancer, Lung Cancer	Observational	Recruiting	2026-04	China
Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT NCT07689630 · ClinicalTrials.gov ↗ · Graft Versus Host Disease, Hematologic Neoplasms Drug: Methotrexate	Phase 3	Recruiting	2026-05	China
Artificial Intelligence-Assisted vs Surgeon-Planned Trajectories in Freehand Femoral Neck Screw Fixation NCT06937138 · ClinicalTrials.gov ↗ · Femoral Neck Fractures	Not applicable	Recruiting	2025-11	China
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies NCT07309900 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Malignancies	Phase 1	Recruiting	2025-11	China
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment NCT07118813 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (Kidney Cancer)	Observational	Recruiting	2025-08	China
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus NCT06653556 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Phase EARLY_PHASE1	Recruiting	2025-01	China
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis NCT06946199 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA) Drug: Cizutamig	Phase 1	Recruiting	2025-06	China
Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM) NCT06922851 · ClinicalTrials.gov ↗ · Dilated Cardiomyopathy (DCM)	Not applicable	Recruiting	2025-06	China
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus NCT06106906 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1/2	Recruiting	2024-06	China
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation NCT07572669 · ClinicalTrials.gov ↗ · Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease	Phase 2	Recruiting	2025-09	China
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE NCT07031713 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Phase 1	Recruiting	2025-07	China
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia NCT06245746 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Neutropenia, Anemia	Phase 1	Recruiting	2025-02	China
Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis NCT07404891 · ClinicalTrials.gov ↗ · Osteoarthritis Drug: ALT001	Not applicable	Recruiting	2026-03	China
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)	Phase EARLY_PHASE1	Recruiting	2025-09	China

Showing the 100 most recently updated of 168 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

63 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 23 more in the trial list above.

Conditions in Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

222 conditions

Gastric Cancer6 Pancreatic Cancer6 Systemic Lupus Erythematosus (SLE)5 Lung Cancer5 Bronchiectasis4 Sepsis4 Multiple Myeloma4 Breast Cancer4 Systemic Lupus Erythematosus4 Rectal Cancer3 Neoadjuvant Therapy3 Rheumatoid Arthritis (RA)3 Knee Osteoarthritis3Ovarian Insufficiency3Lung Adenocarcinoma2EGFR Activating Mutation2Artificial Intelligence2 Deep Learning2Lung; Node2Inflammatory Response2Immunosuppression2Malignant Neoplasm of Liver2Portal Hypertension Related to Cirrhosis2Locally Advanced Rectal Cancer2

By trial register

Register	Trials	Recruiting
Clinical trials in China	168	108

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Gastric Cancer

Sponsor	Trials
Fujian Medical University	9
Nanfang Hospital, Southern Medical University	8
The First Affiliated Hospital with Nanjing Medical University	5
Chongqing Precision Biotech	4
RemeGen	3
Yunnan Cancer Hospital	3
TORL Biotherapeutics	2
Merus	2
Ono Pharmaceutical	2
Wuhan University	2

Sponsors with the most current trials registered for this condition.

Questions about Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

How many clinical trials does Union Hospital, Tongji Medical College, Huazhong University of Science and Technology sponsor?

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 168 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials recruiting?

Yes. 108 of its 168 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Union Hospital, Tongji Medical College, Huazhong University of Science and Technology testing?

Its current trials name 63 drugs and biologicals as interventions. The most frequent are Cadonilimab (3), Cyclophosphamide (3), Nab-paclitaxel (3), Oxaliplatin (3) and Bevacizumab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology clinical trials